Loading...
OTCM
NWBO
Market cap358mUSD
Dec 05, Last price  
0.23USD
1D
-0.34%
1Q
-7.84%
Jan 2017
-33.10%
IPO
-99.98%
Name

Northwest Biotherapeutics Inc

Chart & Performance

D1W1MN
OTCM:NWBO chart
P/E
—
P/S
259.53
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.10%
Rev. gr., 5y
-10.53%
Revenues
1m
-28.47%
124,000800,00010,00010,00010,00010,00010,000772,000809,0001,454,0001,739,000623,000336,000412,0002,410,0001,291,0001,005,0001,683,0001,932,0001,382,000
Net income
-84m
L+33.83%
-9,937,000-1,395,000-21,257,000-22,331,000-25,271,000-27,368,000-32,830,000-67,320,000-65,789,000-135,634,000-114,741,000-80,214,000-73,143,000-35,794,000-23,572,000-538,365,000179,126,000-136,848,000-62,599,000-83,778,000
CFO
-57m
L+6.30%
-4,184,000-6,930,000-14,601,000-15,587,000-4,677,000-6,376,000-14,707,000-22,754,000-37,800,000-54,576,000-78,608,000-55,652,000-36,495,000-34,586,000-31,859,000-32,093,000-38,299,000-52,775,000-53,637,000-57,017,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
URL
https://nwbio.com/
IPO date
Dec 14, 2001
Employees
22
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT